Ulf Aasebø

Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up

Stein Sundstrøm, Roy M. Bremnes, Stein Kaasa et al. · Journal of Clinical Oncology · 2002 · 501 citations

A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)

Kazimierz Roszkowski, Maciej Krzakowski, A P Smith et al. · Lung Cancer · 2000 · 308 citations

Oncology, Cancer Management, Clinical Trials +8

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten et al. · Journal of Clinical Oncology · 2009 · 289 citations · Full text

Cancer Quality, Gemcitabine Plus Carboplatin, Cancer Management +17

The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

Roy M. Bremnes, Stein Sundstrøm, Ulf Aasebø et al. · Lung Cancer · 2003 · 191 citations

Prognostic Factors, Prognostic Biomarkers, Minimum 5 +8

Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival: A National Phase III Trial

Stein Sundstrøm, Roy M. Bremnes, Ulf Aasebø et al. · Journal of Clinical Oncology · 2004 · 175 citations · Full text